AtriCure, Inc. (NASDAQ:ATRC) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 14.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,400 shares of the medical device company’s stock after acquiring an additional 1,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in AtriCure were worth $478,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Knights of Columbus Asset Advisors LLC increased its position in AtriCure by 165.8% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 123,540 shares of the medical device company’s stock worth $4,409,000 after purchasing an additional 77,055 shares in the last quarter. CenterBook Partners LP acquired a new stake in AtriCure during the 3rd quarter worth approximately $770,000. Decheng Capital Management III Cayman LLC acquired a new stake in AtriCure during the 3rd quarter worth approximately $2,026,000. Envestnet Asset Management Inc. increased its position in AtriCure by 127.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 116,990 shares of the medical device company’s stock worth $5,124,000 after purchasing an additional 65,653 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in AtriCure by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,689,883 shares of the medical device company’s stock worth $205,417,000 after purchasing an additional 43,431 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Insiders Place Their Bets

In other AtriCure news, insider Justin J. Noznesky sold 1,500 shares of AtriCure stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total value of $55,080.00. Following the completion of the transaction, the insider now owns 74,284 shares of the company’s stock, valued at $2,727,708.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other AtriCure news, insider Karl S. Dahlquist sold 8,231 shares of AtriCure stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $37.36, for a total value of $307,510.16. Following the completion of the transaction, the insider now owns 52,839 shares of the company’s stock, valued at $1,974,065.04. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Justin J. Noznesky sold 1,500 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the transaction, the insider now directly owns 74,284 shares of the company’s stock, valued at approximately $2,727,708.48. The disclosure for this sale can be found here. Insiders sold a total of 13,116 shares of company stock valued at $468,797 over the last 90 days. 3.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $46.00 target price on shares of AtriCure in a research report on Wednesday, April 10th. Stifel Nicolaus lowered their price objective on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating for the company in a research report on Friday, February 16th. StockNews.com downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th. UBS Group increased their price objective on shares of AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Finally, Oppenheimer raised shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a research report on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.63.

AtriCure Stock Performance

AtriCure stock opened at $24.76 on Thursday. The stock has a market cap of $1.20 billion, a P/E ratio of -37.52 and a beta of 1.38. The company has a current ratio of 3.57, a quick ratio of 2.66 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average of $29.30 and a 200-day moving average of $33.32. AtriCure, Inc. has a 52 week low of $22.07 and a 52 week high of $59.61.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, February 15th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. The firm had revenue of $106.50 million for the quarter, compared to analysts’ expectations of $103.68 million. AtriCure had a negative return on equity of 7.55% and a negative net margin of 7.62%. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period last year, the business posted ($0.09) earnings per share. On average, analysts expect that AtriCure, Inc. will post -0.71 EPS for the current fiscal year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.